Biochemistry-first molecular monograph · Version 5.0 · Updated 23 August 2026
CJC-1295 with DAC
A prolonged growth-hormone-releasing hormone analogue
DAC-mediated albumin association converts a short hypothalamic releasing signal into multi-day pituitary stimulation while retaining detectable pulsatility.
This monograph is restricted to CJC-1295 containing the drug-affinity complex (DAC). It does not discuss a no-DAC construct as though it were the same molecule and does not discuss a CJC-1295 plus ipamorelin mixture or laboratory cocktail.
This monograph begins with the molecule and follows the causal chain through biochemistry, cellular mechanism, exposure and integrated physiology. Population studies enter only at the terminal stress-test: useful for the proposition actually tested, incapable of defining the molecule or replacing the causal model.
Epistemological position
The causal chain carries the science.
Identity establishes what exists. Biochemistry establishes what can react. Pharmacology establishes whether the reaction is reachable. Physiology establishes what the system does with it. Statistical human observation comes last and adjudicates only the route, exposure, population and outcome actually studied.
A population average cannot identify a molecule, create a mechanism or decide an individual response. A demonstrated mechanism remains bounded by the causal step shown; a terminal study can confirm or refute its translation under specified conditions, never rewrite the underlying chemistry.
Molecular dossier
The entity before the outcome.
- ENTITY
- Tetrasubstituted GRF(1–29) analogue bearing a drug-affinity complex
- BIOCHEMICAL CLASS
- Albumin-binding GHRH-receptor agonist
- PRIMARY SYSTEM
- GHRHR → pulsatile GH → IGF-1 axis
- IDENTITY BOUNDARY
- CJC-1295 with DAC is distinct from a no-DAC GRF analogue and from every combination product. The albumin-reactive moiety is part of the pharmacological identity. Nomenclature must therefore preserve both the releasing-hormone analogue and the affinity complex: omitting DAC collapses two different concentration-time experiments into one name and makes downstream attribution scientifically unstable.
Action ledger
Describe the action before judging its value.
Benefit is a downstream clinical judgement. The scientific object is the action itself: what moves, under which exposure, in which biological state, and where the inference stops.
Attributed biochemical action
DAC-mediated albumin association converts a short hypothalamic releasing signal into multi-day pituitary stimulation while retaining detectable pulsatility.
Exposure and reachability
Randomised ascending-dose studies in healthy adults estimated a half-life of approximately 5.8–8.1 days. A single injection increased mean GH for at least six days and IGF-1 for approximately nine to eleven days.
Physiological direction is contextual
Prolonged GHRH-receptor stimulation changes a regulated endocrine axis rather than supplying a simple replacement signal. Pulsatility, hepatic IGF-1 production, glucose handling, fluid balance, sleep-disordered breathing and negative feedback determine the organismal consequence. An IGF-1 rise establishes axis engagement; it does not, by itself, establish repair or favourable body composition.
Individual adjudication boundary
The path from sustained GH/IGF-1 movement to net benefit rather than glycaemic, fluid-retention or proliferative cost. A rise in GH or IGF-1 is proof of target engagement, not proof of recovery, body recomposition, sleep improvement or longevity.
Causal map with terminal adjudication
The scientific hierarchy is explicit.
I–III established for the DAC construct and GH/IGF-1 target engagement
DAC-mediated albumin association converts a short hypothalamic releasing signal into multi-day pituitary stimulation while retaining detectable pulsatility.
Class D/E beyond endocrine pharmacodynamics; patient-important outcomes remain unestablished
This descriptor applies only to the named route, population and outcome. It neither ranks nor creates the molecule’s biochemical science.
Translation boundary
The path from sustained GH/IGF-1 movement to net benefit rather than glycaemic, fluid-retention or proliferative cost.
What must not be inferred
A rise in GH or IGF-1 is proof of target engagement, not proof of recovery, body recomposition, sleep improvement or longevity.
Historical and international corpus
Old research is not absent research.
CJC-1295 with DAC is a 2000s engineered entity derived from older GHRH physiology. Only the DAC construct owns the multi-day pharmacokinetic and endocrine observations.
The literature is strong for construct identity, albumin binding, exposure and GH/IGF-1 target engagement, but thin for patient-important outcomes.
Older endocrine physiology defines the axis, not the product
Hypothalamic-pituitary GH physiology predates CJC-1295. The drug-affinity complex changes residence time so profoundly that earlier short GHRH fragments cannot supply its exposure assumptions.[2][3]
Compact but direct construct-specific programme
The defining publications established albumin-linked persistence, multi-day hormone responses and downstream serum-protein perturbation. A small corpus can be mechanistically powerful when it directly resolves identity and exposure.[1][2][3][4]
Mechanistic and biochemical calculus
Constraint, measurement and inference are not the same claim.
A biochemical proposition can be powerful without a clinical trial, but its premises, exposure and domain must remain explicit. Each statement below is labelled by the operation that supports it.
DAC changes the pharmacological entity
Covalent albumin association alters effective molecular size, clearance and concentration-time behaviour. A no-DAC peptide cannot inherit the reported half-life by nomenclature.[1][3]
Exposure and endocrine response occupy different clocks
The reported apparent half-life was approximately 5.8–8.1 days; GH and IGF-1 responses persisted on different multi-day intervals. These clocks must be modelled separately rather than called a single duration of action.[1]
Endocrine engagement is not an outcome function
No equation converts a given GH or IGF-1 increment into recovery, sleep, body composition or longevity. Feedback, age, glucose state and tissue sensitivity leave that mapping unresolved.[1][4]
Complete scientific web editionOpen the full causal analysis and referencesThe decision-grade summary remains above. The complete publication stays available here and as a downloadable PDF.
Causal architecture
From molecular event to organismal hypothesis.
DAC changes molecular residence
The reactive affinity complex binds circulating albumin and protects the GRF analogue from the rapid clearance expected of the unmodified releasing fragment. This modification creates the multi-day exposure profile and makes no-DAC material a different pharmacological entity.[1][3]
IGF-1 is a downstream mediator and boundary
GH changes hepatic and tissue IGF-1 signalling, substrate handling, fluid balance and protein turnover. Those pathways can support anabolism while also creating glycaemic and proliferative tensions. Direction of biomarker movement alone cannot settle the net organismal effect.[1][4]
Pulsatility is not physiological equivalence
Detectable GH pulses during prolonged stimulation are mechanistically relevant, yet pulse amplitude, integrated exposure and feedback can differ from baseline physiology. Preserved temporal structure must not be used to claim restored endocrine homeostasis without direct measurement.[1][2]
What is established
✓ DAC construct defined
✓ Albumin binding
✓ Human GH/IGF-1 pharmacodynamics
What remains unresolved
? Patient-relevant efficacy
? Long-term metabolic consequences
? Outcome-specific dose architecture
Causal hierarchy
Seven evidentiary layers. No category substitution.
Levels I-V build the causal and translational model. Human observations and controlled clinical trials then test the complete proposition under the route, exposure, population and outcome actually studied. A trial is terminal adjudication, not the source of molecular truth.
IMolecular identity and chemistryWhat exact sequence, terminal chemistry, formulation and route exist?
IIBiochemistry and target architectureWhat reactions, binding events and signalling steps are physically possible?
IIICells and ex-vivo tissuesWhat changes in the relevant cell or isolated tissue system?
IVAnimal and in-vivo pharmacologyDoes exposure reach the mechanism in an integrated organism?
VIntegrated physiology and translationHow do tissue state, feedback, dose and individual terrain alter the response?
VIHuman PK and observational signalIs the entity present, tolerated and associated with a signal in humans?
VIIControlled clinical trialsDoes the specified protocol change a prespecified patient-relevant outcome?
Method applied to CJC-1295 with DAC
Where this molecule’s evidence can, and cannot, travel.
The complete corpus-wide attribution rules are published in the scientific methodology. This is their molecule-specific application.
Entity rule applied
CJC-1295 with DAC is distinct from a no-DAC GRF analogue and from every combination product. The albumin-reactive moiety is part of the pharmacological identity. Nomenclature must therefore preserve both the releasing-hormone analogue and the affinity complex: omitting DAC collapses two different concentration-time experiments into one name and makes downstream attribution scientifically unstable.
Reachability rule applied
Randomised ascending-dose studies in healthy adults estimated a half-life of approximately 5.8–8.1 days. A single injection increased mean GH for at least six days and IGF-1 for approximately nine to eleven days. The decisive exposure boundary for CJC-1295 with DAC therefore remains molecule-, formulation- and route-specific.
Causal-strength rule applied
DAC-mediated albumin association converts a short hypothalamic releasing signal into multi-day pituitary stimulation while retaining detectable pulsatility. This places the present causal depth at i–iii established for the dac construct and gh/igf-1 target engagement. That grade describes which links in the mechanism have been demonstrated; it is not a consumer rating and cannot be converted into a general promise of benefit.
Human-adjudication rule applied
Class D/E beyond endocrine pharmacodynamics; patient-important outcomes remain unestablished. This terminal descriptor answers only the population, route, exposure and outcome actually observed; it neither upgrades nor cancels a different link in CJC-1295 with DAC’s causal chain.
Translation rule applied
The path from sustained GH/IGF-1 movement to net benefit rather than glycaemic, fluid-retention or proliferative cost. A rise in GH or IGF-1 is proof of target engagement, not proof of recovery, body recomposition, sleep improvement or longevity.
Falsification rule applied
The interpretation must change if any of its decisive propositions fail. For CJC-1295 with DAC, the predeclared tests are: Failure of albumin association or multi-day exposure would invalidate DAC-based attribution. IGF-1 elevation without a prespecified functional benefit would refute biomarker-as-benefit reasoning. Deteriorating glucose, oedema or sleep-disordered breathing would falsify a net-benefit claim for that phenotype. These are active boundaries on the conclusion, not research questions appended after a favourable narrative.
Foundational synthesis
Molecular identity and entity resolution
Here CJC-1295 means the DAC construct: a tetrasubstituted GRF(1–29) analogue bearing a drug-affinity complex that binds albumin. A shorter-acting no-DAC construct is a different entity and cannot inherit its pharmacokinetics.
Foundational synthesis
Biochemical mechanism and target architecture
CJC-1295 with DAC engages the GHRH receptor and prolongs stimulation of pulsatile growth-hormone secretion, with downstream IGF-1 elevation. Target engagement does not itself establish recovery, body-composition, sleep or longevity benefit.
Foundational synthesis
In-vivo pharmacology and exposure
Randomised ascending-dose studies in healthy adults estimated a half-life of approximately 5.8–8.1 days. A single injection increased mean GH for at least six days and IGF-1 for approximately nine to eleven days.
Foundational synthesis
Integrated physiology and individual terrain
Prolonged GHRH-receptor stimulation changes a regulated endocrine axis rather than supplying a simple replacement signal. Pulsatility, hepatic IGF-1 production, glucose handling, fluid balance, sleep-disordered breathing and negative feedback determine the organismal consequence. An IGF-1 rise establishes axis engagement; it does not, by itself, establish repair or favourable body composition.
Foundational synthesis
Terminal human stress-test
Human studies establish prolonged GH-axis engagement and preservation of pulsatility. They do not establish patient-relevant outcomes in recovery, body composition or healthy ageing.
Foundational synthesis
Counterevidence and causal boundaries
An IGF-1 rise is a pharmacodynamic signal, not a clinical success. Oedema, paraesthesia, arthralgia, glycaemic deterioration, sleep-apnoea context and growth signalling remain biologically relevant boundaries.
Foundational synthesis
Scientific conclusion
CJC-1295 with DAC has defined identity and credible human pharmacodynamics. Clinical claims must remain narrower than verified GH/IGF-1 target engagement and must never be transferred to a no-DAC construct.
Extended analysis
Entity resolution and albumin affinity
CJC-1295 with DAC is a tetrasubstituted GRF(1-29) analogue carrying a reactive drug-affinity complex. Covalent binding to albumin is not a cosmetic modification: it transforms residence time and makes the DAC construct a different pharmacological entity from shorter-acting GRF analogues sold under similar names.[1][3]
Evidence attribution begins with the construct used in the human studies. The prolonged half-life, multi-day GH elevation and sustained IGF-1 response belong to CJC-1295 with DAC. They cannot be inherited by a no-DAC peptide and cannot be extrapolated to a combination product.[1][2]
Extended analysis
Pituitary mechanism and endocrine dynamics
The peptide activates the growth-hormone-releasing hormone receptor on pituitary somatotrophs. This increases endogenous GH secretion and downstream hepatic and tissue IGF-1 signalling. The biological programme remains mediated by an intact hypothalamic-pituitary axis rather than by administration of exogenous GH itself.[1][2]
Pulsatility was reported to remain detectable despite prolonged exposure. That observation is mechanistically important, but preservation of pulses does not prove physiological equivalence. Pulse amplitude, integrated exposure, feedback, sleep, glucose and baseline endocrine state can all change the downstream phenotype.[1][2]
Extended analysis
Human pharmacokinetics and target engagement
Ascending-dose studies in healthy adults estimated an apparent half-life of approximately 5.8 to 8.1 days. A single subcutaneous injection increased mean GH for at least six days and IGF-1 for approximately nine to eleven days; repeated administration produced cumulative IGF-1 elevation.[1]
These findings establish exposure and endocrine target engagement. They do not establish improvement in sleep, recovery, body composition, cognition or longevity. GH and IGF-1 are intermediate biological signals whose relationship with benefit and harm depends on age, metabolic state, tissue sensitivity and duration.[1][4]
Extended analysis
Proteomic response and interpretation
A small proteomic study examined sera from eleven healthy young men before and one week after CJC-1295. Several protein spots changed, including apolipoprotein A1 and transthyretin isoforms. This demonstrates downstream biological perturbation but does not establish clinical utility or a validated response biomarker.[4]
The proteomic observations illustrate why a rise in IGF-1 should not be treated as the whole mechanism. Growth signalling reorganises multiple protein and tissue processes. The direction and clinical meaning of that reorganisation require outcome-specific study.[4]
Extended analysis
Boundaries of clinical inference
Potential boundaries arise from the same axis that creates the desired pharmacology: oedema, paraesthesia, arthralgia, worsening glucose regulation, sleep-apnoea context and proliferative signalling. These are mechanistic monitoring domains, not proof that harm will occur in every exposed person.[1][4]
The human programme is strong for identity, exposure and GH/IGF-1 pharmacodynamics but thin for patient-important outcomes. Any proposition beyond target engagement therefore requires a defined phenotype, comparator, functional endpoint and stopping rule rather than a generic optimisation narrative.[1][2][4]
Evidence atlas
Every claim keeps its experimental address.
10 claim units are mapped to their evidentiary layer, experimental frame and source records. The layer describes what the evidence can answer; it is not a popularity score.
| Layer | Experimental frame | Finding and boundary | Sources |
|---|---|---|---|
| IMolecular identity | Entity resolution and albumin affinity · claim 1 | CJC-1295 with DAC is a tetrasubstituted GRF(1-29) analogue carrying a reactive drug-affinity complex. Covalent binding to albumin is not a cosmetic modification: it transforms residence time and makes the DAC construct a different pharmacological entity from shorter-acting GRF analogues sold under similar names. | [1][3] |
| IMolecular identity | Entity resolution and albumin affinity · claim 2 | Evidence attribution begins with the construct used in the human studies. The prolonged half-life, multi-day GH elevation and sustained IGF-1 response belong to CJC-1295 with DAC. They cannot be inherited by a no-DAC peptide and cannot be extrapolated to a combination product. | [1][2] |
| IVIntegrated in-vivo model | Pituitary mechanism and endocrine dynamics · claim 1 | The peptide activates the growth-hormone-releasing hormone receptor on pituitary somatotrophs. This increases endogenous GH secretion and downstream hepatic and tissue IGF-1 signalling. The biological programme remains mediated by an intact hypothalamic-pituitary axis rather than by administration of exogenous GH itself. | [1][2] |
| VIHuman exposure or signal | Pituitary mechanism and endocrine dynamics · claim 2 | Pulsatility was reported to remain detectable despite prolonged exposure. That observation is mechanistically important, but preservation of pulses does not prove physiological equivalence. Pulse amplitude, integrated exposure, feedback, sleep, glucose and baseline endocrine state can all change the downstream phenotype. | [1][2] |
| VIHuman exposure or signal | Human pharmacokinetics and target engagement · claim 1 | Ascending-dose studies in healthy adults estimated an apparent half-life of approximately 5.8 to 8.1 days. A single subcutaneous injection increased mean GH for at least six days and IGF-1 for approximately nine to eleven days; repeated administration produced cumulative IGF-1 elevation. | [1] |
| VIHuman exposure or signal | Human pharmacokinetics and target engagement · claim 2 | These findings establish exposure and endocrine target engagement. They do not establish improvement in sleep, recovery, body composition, cognition or longevity. GH and IGF-1 are intermediate biological signals whose relationship with benefit and harm depends on age, metabolic state, tissue sensitivity and duration. | [1][4] |
| IVIntegrated in-vivo model | Proteomic response and interpretation · claim 1 | A small proteomic study examined sera from eleven healthy young men before and one week after CJC-1295. Several protein spots changed, including apolipoprotein A1 and transthyretin isoforms. This demonstrates downstream biological perturbation but does not establish clinical utility or a validated response biomarker. | [4] |
| IVIntegrated in-vivo model | Proteomic response and interpretation · claim 2 | The proteomic observations illustrate why a rise in IGF-1 should not be treated as the whole mechanism. Growth signalling reorganises multiple protein and tissue processes. The direction and clinical meaning of that reorganisation require outcome-specific study. | [4] |
| IVIntegrated in-vivo model | Boundaries of clinical inference · claim 1 | Potential boundaries arise from the same axis that creates the desired pharmacology: oedema, paraesthesia, arthralgia, worsening glucose regulation, sleep-apnoea context and proliferative signalling. These are mechanistic monitoring domains, not proof that harm will occur in every exposed person. | [1][4] |
| VIHuman exposure or signal | Boundaries of clinical inference · claim 2 | The human programme is strong for identity, exposure and GH/IGF-1 pharmacodynamics but thin for patient-important outcomes. Any proposition beyond target engagement therefore requires a defined phenotype, comparator, functional endpoint and stopping rule rather than a generic optimisation narrative. | [1][2][4] |
Methods and coverage
A reproducible boundary, not an implied exhaustive review.
This is a curated mechanistic monograph built from primary records. It does not claim systematic-review completeness. Absence of a retrieved result is not evidence that an effect is absent.
- SEARCH SURFACE
- PubMed/MEDLINE primary records, Russian-language indexed abstracts, and reference-chaining for entity-defining, historical and translational studies. Language, geography, regulatory status and journal fashion are not evidence grades.
- QUERY FRAME
- CJC-1295 with DAC · drug affinity complex · GHRH receptor · growth hormone · IGF-1 · albumin binding
- EVIDENCE CUTOFF
- 23 August 2026
- ENTITY EXCLUSION
- CJC-1295 with DAC is distinct from a no-DAC GRF analogue and from every combination product. The albumin-reactive moiety is part of the pharmacological identity. Nomenclature must therefore preserve both the releasing-hormone analogue and the affinity complex: omitting DAC collapses two different concentration-time experiments into one name and makes downstream attribution scientifically unstable.
- TRACEABILITY
- 10 extended claim units plus 2 historical records and 3 mechanistic-calculus records; 4 cited records in the complete corpus.
- INTERPRETIVE RULE
- Identity → physical constraint → measured reaction or binding → reachable exposure → system response → outcome. Statistical significance does not manufacture mechanism; mechanistic plausibility does not manufacture a patient outcome.
Falsification map
What could make the proposition wrong?
A scientific monograph must state not only why a mechanism may hold, but what observation would weaken or overturn the inference.
- 01Failure of albumin association or multi-day exposure would invalidate DAC-based attribution.
- 02IGF-1 elevation without a prespecified functional benefit would refute biomarker-as-benefit reasoning.
- 03Deteriorating glucose, oedema or sleep-disordered breathing would falsify a net-benefit claim for that phenotype.
Research agenda
What would materially change the conclusion?
A useful research agenda resolves the weakest link in the identity-to-outcome chain. It does not merely add more observations of the same type.
- 01Outcome-specific trials using the exact DAC construct
- 02Longitudinal glucose and sleep-apnoea effects
- 03Dose-exposure-response modelling beyond IGF-1
- 04Body-composition and functional endpoints
- 05Long-term feedback and endocrine recovery after discontinuation
Cited primary evidence corpus
4 source records used in this publication.
Reference numbers resolve directly to indexed records. This corpus documents the claims made here; it is not presented as an exhaustive systematic-review search. Index access does not upgrade the evidentiary class of a study.
- [1]Teichman et al. J Clin Endocrinol Metab. 2006;91:799–805.PMID 16352683 ↗
- [2]Ionescu & Frohman. J Clin Endocrinol Metab. 2006;91:4792–4797.PMID 17018654 ↗
- [3]Jetté et al. Endocrinology. 2005;146:3052–3058.PMID 15817669 ↗
- [4]Chung et al. Activation of the GH/IGF-1 axis by CJC-1295 results in serum protein profile changes. Growth Horm IGF Res. 2009.PMID 19386527 ↗
Permanent citation
Cite this publication
Wibowo V. CJC-1295 with DAC: Biochemical, Mechanistic and Physiological Monograph. Clinic Terrain Clinical Intelligence Unit. Version 5.0. Updated 23 August 2026.
https://www.clinicterrain.com/research/peptides/cjc-1295-with-dacPublication and reference-verification method →Authorship and accountability
Valentine Wibowo, Clinical Researcher, Clinic Terrain Clinical Intelligence Unit, performed the conceptualisation, evidence synthesis, scientific interpretation and drafting. dr. I Wayan Cahyadi Surya Distira Putra, MPH completed medical review and approved the publication. Internal medical review is not represented as independent peer review.
No new patient data or human research were undertaken. The author and reviewer declare no personal financial competing interests. Clinic Terrain and Klinik Pratama Cepat Sehat provide clinical services; that institutional relationship is disclosed.